Clinical Efficacy of The Postbiotic Drug Biodonatum In Children with Pneumonia and Reduced Sensitivity to Antibiotic Therapy
Abstract
Community-acquired pneumonia remains one of the leading causes of morbidity and mortality in the pediatric population worldwide, with antimicrobial resistance constituting a mounting threat to successful clinical management. The emergence and rapid dissemination of antibiotic-resistant bacterial strains have substantially reduced the therapeutic arsenal available to clinicians treating childhood pneumonia, necessitating the investigation of adjunctive treatment strategies capable of enhancing clinical recovery and restoring microbial equilibrium. This study aimed to evaluate the clinical efficacy, safety profile, and microbiome-modulating effects of the postbiotic preparation Biodonatum when administered as an adjunct to standard antibiotic therapy in children diagnosed with community-acquired pneumonia and demonstrating reduced sensitivity to first-line antibiotic agents. A prospective, randomized, controlled clinical trial was conducted at the Department of Pediatric Infectious Diseases, Tashkent State Medical University, enrolling 90 children aged 3 to 14 years with confirmed pneumonia and documented reduced antibiotic susceptibility. Participants were randomized into two equal groups: the intervention group (n = 45) received standard antibiotic therapy supplemented with Biodonatum, while the control group (n = 45) received standard antibiotic therapy alone. Clinical, laboratory, and microbiological parameters were assessed at baseline and on days 7 and 14 of treatment.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 90 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.